ClinVar Miner

Variants with conflicting interpretations studied for Non-small cell lung cancer

Coded as:
Minimum review status of the submission for Non-small cell lung cancer: Y axis collection method of the submission for Non-small cell lung cancer:
Minimum review status of the other submission: Collection method of the other submission:
Minimum conflict level:
ClinVar version:

If a variant has more than two submissions, it may have multiple conflicts and therefore be counted in more than one conflict column. If this is the case, the "Variants with any kind of conflict" cell will be less than the sum of the conflicted variants cells to its left.

Variants with only 1 submission Variants with at least 2 submissions and no conflicts Variants with a synonymous conflict
(e.g. benign vs non-pathogenic)
Variants with a confidence conflict
(e.g. benign vs likely benign)
Variants with a benign or likely benign vs uncertain conflict Variants with a category conflict
(e.g. benign vs affects)
Variants with a clinically significant conflict
(e.g. benign vs pathogenic)
Variants with any kind of conflict
45 37 5 49 0 10 5 56

Significance breakdown #

In the table below, cells that correspond to a term paired with itself represent synonymous conflicts, i.e. variants that have been annotated with different terms that map to the same standard term. To compare the terms that were actually submitted, check the box in the filters section at the top of this page.

All conditions
Non-small cell lung cancer pathogenic likely pathogenic uncertain significance drug response protective
pathogenic 5 42 2 8 1
likely pathogenic 11 0 3 3 1

Condition to condition summary #

Total conditions: 72
Download table as spreadsheet
Condition Variants with only 1 submission Variants with at least 2 submissions and no conflicts Variants with a synonymous conflict
(e.g. benign vs non-pathogenic)
Variants with a confidence conflict
(e.g. benign vs likely benign)
Variants with a benign or likely benign vs uncertain conflict Variants with a category conflict
(e.g. benign vs affects)
Variants with a clinically significant conflict
(e.g. benign vs pathogenic)
Variants with any kind of conflict
Lung adenocarcinoma 0 14 0 24 0 0 0 24
Malignant melanoma of skin 0 4 0 21 0 0 0 21
Adenocarcinoma of stomach 0 3 0 17 0 0 0 17
Malignant neoplasm of body of uterus 0 3 0 16 0 0 0 16
Acute myeloid leukemia 0 1 0 14 0 0 0 14
Multiple myeloma 0 3 0 14 0 0 0 14
Transitional cell carcinoma of the bladder 0 4 0 14 0 0 0 14
Squamous cell lung carcinoma 0 8 0 13 0 0 0 13
Glioblastoma 0 5 0 12 0 0 0 12
Hepatocellular carcinoma 0 2 0 11 0 0 0 11
Neoplasm of brain 0 4 0 11 0 0 0 11
Squamous cell carcinoma of the head and neck 0 4 0 10 0 1 0 11
Adenocarcinoma of prostate 0 1 0 10 0 0 0 10
Ovarian Serous Cystadenocarcinoma 0 2 0 8 0 0 0 8
Renal cell carcinoma, papillary, 1 0 1 0 8 0 0 0 8
Adrenocortical carcinoma 0 2 0 7 0 0 0 7
Carcinoma of esophagus 0 1 0 7 0 0 0 7
Cutaneous melanoma 0 16 0 7 0 0 0 7
Neoplasm 0 0 0 7 0 0 0 7
Uterine cervical neoplasms 0 1 0 7 0 0 0 7
Brainstem glioma 0 0 0 6 0 0 0 6
Chronic lymphocytic leukemia 0 2 0 6 0 0 0 6
Neoplasm of the thyroid gland 0 13 0 6 0 0 0 6
Pancreatic adenocarcinoma 0 1 0 6 0 0 0 6
Myelodysplastic syndrome 0 0 0 5 0 0 0 5
Nasopharyngeal Neoplasms 0 1 0 5 0 0 0 5
Neoplasm of the large intestine 0 40 0 5 0 0 0 5
Tyrosine kinase inhibitor response 0 0 0 0 0 5 0 5
Uterine Carcinosarcoma 0 0 0 5 0 0 0 5
Non-small cell lung cancer 114 20 0 4 0 0 0 4
Papillary renal cell carcinoma, sporadic 0 3 0 4 0 0 0 4
Small cell lung cancer 0 1 0 4 0 0 0 4
not provided 0 13 0 3 0 0 1 4
Congenital lipomatous overgrowth, vascular malformations, and epidermal nevi 0 0 3 0 0 0 0 3
Lung cancer 0 4 0 3 0 0 0 3
Medulloblastoma 0 0 0 3 0 0 0 3
Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, somatic 0 0 0 0 0 3 0 3
Ovarian Neoplasms 0 11 0 3 0 0 0 3
not specified 0 2 0 0 0 0 3 3
Carcinoma of gallbladder 0 0 0 2 0 0 0 2
Neoplasm of the breast 0 10 0 2 0 0 0 2
Rasopathy 0 5 0 1 0 0 1 2
Squamous cell carcinoma of the skin 0 0 0 2 0 0 0 2
Vascular Tumors Including Pyogenic Granuloma 0 0 0 2 0 0 0 2
erlotinib response - Efficacy 0 0 0 0 0 2 0 2
gefitinib response - Efficacy 0 0 0 0 0 2 0 2
Adenocarcinoma of lung, response to tyrosine kinase inhibitor in, somatic 0 0 0 0 0 1 0 1
Carcinoma of pancreas 0 1 0 1 0 0 0 1
Cerebral arteriovenous malformation 0 1 0 1 0 0 0 1
Chronic myelogenous leukemia 0 1 0 1 0 0 0 1
Cowden syndrome 0 2 0 1 0 0 0 1
EGFR-related lung cancer 0 0 0 1 0 0 0 1
Endometrial Endometrioid Adenocarcinoma, Variant with Squamous Differentiation 0 0 0 1 0 0 0 1
Gastrointestinal stroma tumor 0 2 0 1 0 0 0 1
Head and Neck Neoplasms 0 1 0 1 0 0 0 1
Histone Methylation Therapy response 0 0 0 0 0 1 0 1
Juvenile myelomonocytic leukemia 0 4 0 1 0 0 0 1
Malignant tumor of floor of mouth 0 0 0 1 0 0 0 1
Medullary thyroid carcinoma 0 0 0 1 0 0 0 1
Megalencephaly cutis marmorata telangiectatica congenita 0 1 1 0 0 0 0 1
Meningeal Neoplasms 0 0 0 1 0 0 0 1
Neoplasm of the colon 0 0 0 1 0 0 0 1
Nevus sebaceous 0 1 0 1 0 0 0 1
Nonsmall cell lung cancer, resistance to tyrosine kinase inhibitor in 0 0 0 0 0 1 0 1
Osteosarcoma 0 1 0 1 0 0 0 1
PIK3CA related overgrowth spectrum 0 2 0 1 0 0 0 1
Prostate neoplasm 0 1 0 1 0 0 0 1
Proteus syndrome 0 0 1 0 0 0 0 1
RAS Inhibitor response 0 0 0 0 0 1 0 1
carboplatin, docetaxel, erlotinib, gemcitabine, and paclitaxel response - Efficacy 0 0 0 0 0 1 0 1
cetuximab response - Dosage 0 0 0 0 0 1 0 1
panitumumab response - Dosage 0 0 0 0 0 1 0 1

All variants with conflicting interpretations #

Total variants: 56
Download table as spreadsheet
HGVS dbSNP
NM_002524.3(NRAS):c.182A>C (p.Gln61Pro) rs11554290
NM_002524.3(NRAS):c.182A>G (p.Gln61Arg) rs11554290
NM_002524.3(NRAS):c.34G>A (p.Gly12Ser) rs121913250
NM_002524.3(NRAS):c.34G>C (p.Gly12Arg) rs121913250
NM_002524.3(NRAS):c.34G>T (p.Gly12Cys) rs121913250
NM_002524.3(NRAS):c.35G>A (p.Gly12Asp) rs121913237
NM_002524.4(NRAS):c.181C>A (p.Gln61Lys) rs121913254
NM_002524.4(NRAS):c.182A>T (p.Gln61Leu) rs11554290
NM_002524.4(NRAS):c.183A>C (p.Gln61His) rs121913255
NM_002524.4(NRAS):c.35G>C (p.Gly12Ala) rs121913237
NM_002755.3(MAP2K1):c.167A>C (p.Gln56Pro) rs1057519729
NM_002755.3(MAP2K1):c.171G>T (p.Lys57Asn) rs869025608
NM_002755.3(MAP2K1):c.199G>A (p.Asp67Asn) rs727504317
NM_004333.4(BRAF):c.1397G>T (p.Gly466Val) rs121913351
NM_004333.4(BRAF):c.1406G>C (p.Gly469Ala) rs121913355
NM_004333.4(BRAF):c.1406G>T (p.Gly469Val) rs121913355
NM_004333.4(BRAF):c.1780G>A (p.Asp594Asn) rs397516896
NM_004333.4(BRAF):c.1781A>G (p.Asp594Gly) rs121913338
NM_004333.5(BRAF):c.1391G>T (p.Gly464Val) rs121913348
NM_004333.5(BRAF):c.1789C>G (p.Leu597Val) rs121913369
NM_004333.5(BRAF):c.1798G>A (p.Val600Met) rs121913378
NM_004333.5(BRAF):c.1799T>A (p.Val600Glu) rs113488022
NM_004333.5(BRAF):c.1801A>G (p.Lys601Glu) rs121913364
NM_004448.3(ERBB2):c.2313_2324dupATACGTGATGGC (p.Ala775_Gly776insTyrValMetAla) rs397516975
NM_004985.4(KRAS):c.179G>T (p.Gly60Val) rs727503108
NM_004985.4(KRAS):c.183A>C (p.Gln61His) rs17851045
NM_004985.4(KRAS):c.35G>A (p.Gly12Asp) rs121913529
NM_004985.4(KRAS):c.35G>T (p.Gly12Val) rs121913529
NM_005163.2(AKT1):c.49G>A (p.Glu17Lys) rs121434592
NM_005228.4(EGFR):c.2155G>A (p.Gly719Ser) rs28929495
NM_005228.4(EGFR):c.2155G>C (p.Gly719Arg) rs28929495
NM_005228.4(EGFR):c.2155G>T (p.Gly719Cys) rs28929495
NM_005228.4(EGFR):c.2156G>C (p.Gly719Ala) rs121913428
NM_005228.4(EGFR):c.2248G>C (p.Ala750Pro) rs121913229
NM_005228.4(EGFR):c.2281G>T (p.Asp761Tyr) rs121913418
NM_005228.4(EGFR):c.2303G>T (p.Ser768Ile) rs121913465
NM_005228.4(EGFR):c.2303_2311dupGCGTGGACA (p.Asp770_Asn771insSerValAsp) rs397517109
NM_005228.4(EGFR):c.2369C>T (p.Thr790Met) rs121434569
NM_005228.4(EGFR):c.2572C>A (p.Leu858Met) rs121913443
NM_005228.4(EGFR):c.2573T>G (p.Leu858Arg) rs121434568
NM_005228.4(EGFR):c.2582T>A (p.Leu861Gln) rs121913444
NM_006218.3(PIK3CA):c.1633G>C (p.Glu545Gln) rs104886003
NM_006218.3(PIK3CA):c.3129G>A (p.Met1043Ile) rs121913283
NM_006218.3(PIK3CA):c.3139C>T (p.His1047Tyr) rs121913281
NM_006218.4(PIK3CA):c.1624G>A (p.Glu542Lys) rs121913273
NM_006218.4(PIK3CA):c.1624G>C (p.Glu542Gln) rs121913273
NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) rs104886003
NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg) rs121913279
NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu) rs121913279
NM_033360.3(KRAS):c.182A>T (p.Gln61Leu) rs121913240
NM_033360.3(KRAS):c.183A>T (p.Gln61His) rs17851045
NM_033360.3(KRAS):c.34G>A (p.Gly12Ser) rs121913530
NM_033360.3(KRAS):c.34G>T (p.Gly12Cys) rs121913530
NM_033360.3(KRAS):c.35G>C (p.Gly12Ala) rs121913529
NM_033360.3(KRAS):c.38G>A (p.Gly13Asp) rs112445441
NM_033360.3(KRAS):c.38G>T (p.Gly13Val) rs112445441

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.